Assessment of 24,25(OH) 2 D levels does not support FGF23-mediated catabolism of vitamin D metabolites

Kidney International

Volumn 82, Issue 10, 2012, Pages 1061-1070

  Dai, Bing ^a   David, Valentin ^a   Alshayeb, Hala M ^a,b   Showkat, Arif ^a   Gyamlani, Geeta ^c   Horst, Ronald L ^d   Wall, Barry M ^c   Darryl Quarles, L ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Heartland Assays LLC   (United States)

Author keywords

chronic kidney disease; FGF23; parathyroid hormone; vitamin D

Indexed keywords

24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CREATININE; CYTOCHROME; CYTOCHROME P450 24A1; FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; NITROGEN; PARATHYROID HORMONE; UNCLASSIFIED DRUG; UREA;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE EXCRETION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; AGED; ANIMALS; AUTOANTIGENS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; COLLAGEN TYPE IV; CROSS-SECTIONAL STUDIES; DIHYDROXYCHOLECALCIFEROLS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYDROXYLATION; KIDNEY; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; NEPHRITIS, HEREDITARY; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; STEROID HYDROXYLASES; UP-REGULATION; VITAMIN D;

EID: 84868601209     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.222     Document Type: Article

References (43)

1. Wetmore JB, Quarles LD. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract 2009; 5: 24-33.
2. Quarles LD. The bone and beyond: 'Dem bones' are made for more than walking. Nat Med 2011; 17: 428-430.
3. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608.
4. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215. (Pubitemid 41716454)
5. van Husen M, Fischer AK, Lehnhardt A et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010; 78: 200-206.
6. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
7. Stubbs JR, He N, Idiculla A et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2011.
8. Liu S, Guo R, Simpson LG et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003; 278: 37419-37426. (Pubitemid 37175262)
9. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291: E38-E49. (Pubitemid 44035308)
10. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007; 20: 302-308.
11. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000; 277: 494-498.
12. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120-6123. (Pubitemid 43847540)
13. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774. (Pubitemid 44949607)
14. Yu X, Ibrahimi OA, Goetz R et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146: 4647-4656. (Pubitemid 41446602)
15. Li H, Martin AC, David V et al. Compound deletion of FGFR3 and FGFR4 partially rescues the Hyp mouse phenotype. Am J Physiol Endocrinol Metab 2011; 300: E508-E517.
16. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568. (Pubitemid 38542505)
17. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505. (Pubitemid 32488266)
18. White KE, Carn G, Lorenz-Depiereux B et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60: 2079-2086. (Pubitemid 33070451)
19. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptorindependent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095. (Pubitemid 41447065)
20. Tomiyama K, Maeda R, Urakawa I et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci USA 2010; 107: 1666-1671.
21. Beckman MJ, Tadikonda P, Werner E et al. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 1996; 35: 8465-8472. (Pubitemid 26240500)
22. Hoenderop JG, Chon H, Gkika D et al. Regulation of gene expression by dietary Ca2+ in kidneys of 25-hydroxyvitamin D3-1 alpha-hydroxylase knockout mice. Kidney Int 2004; 65: 531-539. (Pubitemid 38130647)
23. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315. (Pubitemid 43673410)
24. Yuan B, Xing Y, Horst RL et al. Evidence for abnormal translational regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase activity in the hyp-mouse. Endocrinology 2004; 145: 3804-3812. (Pubitemid 39037568)
25. Weber TJ, Liu S, Indridason OS et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003; 18: 1227-1234. (Pubitemid 37294915)
26. Helvig CF, Cuerrier D, Hosfield CM et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010; 78: 463-472.
27. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78: 975-980.
28. de Boer IH, Katz R, Chonchol M et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol 2011; 6: 2141-2149.
29. Chonchol M, Cigolini M, Targher G. Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction. Nephrol Dial Transplant 2008; 23: 269-274. (Pubitemid 351767364)
30. Zierold C, Mings JA, DeLuca HF. Parathyroid hormone regulates 25-hydroxyvitamin D(3)-24-hydroxylase mRNA by altering its stability. Proc Natl Acad Sci USA 2001; 98: 13572-13576. (Pubitemid 33115939)
31. Horst RL, Littledike ET, Gray RW et al. Impaired 24,25-dihydroxyvitamin D production in anephric human and pig. J Clin Invest 1981; 67: 274-280. (Pubitemid 11163182)
32. Kumar R, Wiesner R, Scott M et al. Physiology of 24,25-dihydroxyvitamin D3 in normal human subjects. Am J Physiol 1982; 243: E370-E374. (Pubitemid 13253669)
33. Halloran BP, Bikle DD, Levens MJ et al. Chronic 1,25-dihydroxyvitamin D3 administration in the rat reduces the serum concentration of 25-hydroxyvitamin D by increasing metabolic clearance rate. J Clin Invest 1986; 78: 622-628. (Pubitemid 16024794)
34. Ishimura E, Nishizawa Y, Inaba M et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999; 55: 1019-1027. (Pubitemid 29100714)
35. St-Arnaud R. CYP24A1-deficient mice as a tool to uncover a biological activity for vitamin D metabolites hydroxylated at position 24. J Steroid Biochem Mol Biol 2010; 121: 254-256.
36. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
37. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51. (Pubitemid 27494749)
38. Li SA, Watanabe M, Yamada H et al. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 2004; 29: 91-99. (Pubitemid 40260033)
39. Haussler MR, Haussler CA, Whitfield GK et al. The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the 'Fountain of Youth' to mediate healthful aging. J Steroid Biochem Mol Biol 2010; 121: 88-97.
40. Lips P, Chapuy MC, Dawson-Hughes B et al. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999; 9: 394-397. (Pubitemid 29231730)
41. Inouye K, Sakaki T. Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24). Biotechnol Annu Rev 2001; 7: 179-194. (Pubitemid 41081529)
42. Horst RL, Shepard RM, Jorgensen NA et al. The determination of 24,25-dihydroxyvitamin D and 25,26-dihydroxyvitamin D in plasma from normal and nephrectomized man. J Lab Clin Med 1979; 93: 277-285. (Pubitemid 9099254)
43. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 2008; 295: E254-E261.